PRMT5 Inhibition Disrupts Splicing and Stemness in Glioblastoma
ARTICLE https://doi.org/10.1038/s41467-021-21204-5 OPEN PRMT5 inhibition disrupts splicing and stemness in glioblastoma Patty Sachamitr1,2, Jolene C. Ho 2, Felipe E. Ciamponi 3,4, Wail Ba-Alawi5,6, Fiona J. Coutinho1, Paul Guilhamon1,5, Michelle M. Kushida1, Florence M. G. Cavalli1, Lilian Lee1, Naghmeh Rastegar1, Victoria Vu2,5, María Sánchez-Osuna 7, Jasmin Coulombe-Huntington7, Evgeny Kanshin7, Heather Whetstone1, Mathieu Durand8, Philippe Thibault8, Kirsten Hart2,6, Maria Mangos2, Joseph Veyhl2, Wenjun Chen2, Nhat Tran2, Bang-Chi Duong2, Ahmed M. Aman 9, Xinghui Che1, Xiaoyang Lan 1, Owen Whitley10,11, Olga Zaslaver10,11, Dalia Barsyte-Lovejoy 2,12, Laura M. Richards 5,6, Ian Restall 13,14, Amy Caudy 10,11,15, 10,11 16 17,18 17,19,20 1234567890():,; Hannes L. Röst , Zahid Quyoom Bonday , Mark Bernstein , Sunit Das , Michael D. Cusimano19, Julian Spears17,21, Gary D. Bader 10,11, Trevor J. Pugh 5,6,9, Mike Tyers7, Mathieu Lupien 5,6,9, Benjamin Haibe-Kains5,6,9,22,23, H. Artee Luchman13,14,24, Samuel Weiss13,14,24, ✉ ✉ ✉ Katlin B. Massirer3,4, Panagiotis Prinos 2 , Cheryl H. Arrowsmith 2,5,6 & Peter B. Dirks 1,11,17,20,25,26 Glioblastoma (GBM) is a deadly cancer in which cancer stem cells (CSCs) sustain tumor growth and contribute to therapeutic resistance. Protein arginine methyltransferase 5 (PRMT5) has recently emerged as a promising target in GBM. Using two orthogonal-acting inhibitors of PRMT5 (GSK591 or LLY-283), we show that pharmacological inhibition of PRMT5 suppresses the growth of a cohort of 46 patient-derived GBM stem cell cultures, with the proneural subtype showing greater sensitivity.
[Show full text]